---
title: "Novartis Q2 Profit Drops, Net Sales Rise; Reaffirms FY26 Guidance"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293290820.md"
description: "Novartis reported a 19% drop in Q2 net profit to $3.257 billion, despite a 3% rise in net sales to $14.408 billion driven by strong volume growth in priority brands like Kisqali and Kesimpta. The company reaffirmed its FY26 guidance, expecting low single-digit declines in core operating income and low single-digit growth in net sales."
datetime: "2026-07-21T05:25:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293290820.md)
  - [en](https://longbridge.com/en/news/293290820.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293290820.md)
---

# Novartis Q2 Profit Drops, Net Sales Rise; Reaffirms FY26 Guidance

Add  as your preferred news source on Google

 Add Now

Swiss pharmaceutical major Novartis AG (NVS,NOVN.SW) reported Tuesday lower profit in its second quarter, despite higher net sales and volume growth.

Further, the company said it continues to expect fiscal 2026 core operating income to decline low single-digit and net sales to grow low single-digit.

In the second quarter, net income totaled $3.257 billion, down 19 percent from $4.024 billion last year. Earnings per share reached $1.71 for the quarter, 17 percent lower than $2.07 a year ago.

Core net income was $4.578 billion, compared to $4.71 billion last year. Core earnings per share were $2.41, compared to $2.42 in the prior year period.

Operating income dropped 2 percent from last year, while core operating income slightly increased to $5.94 billion. Core operating income margin stood at 41.2 percent, down 70 basis points at constant currency.

Net sales reached $14.408 billion in the second quarter, a growth of 3 percent from $14.054 billion a year ago. Sales growth was 1 percent at constant currency.

The company noted that volume growth contributed 18 percentage points to sales, while generic competition offset 14 percentage points. Pricing had a negative impact of 3 percentage points, though currency provided a positive impact of 2 percentage points.

Sales growth was driven by priority brands, with Kisqali increasing 43 percent at constant currency, Kesimpta rising 32 percent, Scemblix climbing 89 percent, Pluvicto advancing 43 percent, and Leqvio growing 59 percent at constant currency.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

### Related Stocks

- [NVS.US](https://longbridge.com/en/quote/NVS.US.md)
- [NOT.DE](https://longbridge.com/en/quote/NOT.DE.md)

## Related News & Research

- [Weekly Recap: 2nd India ribociclib patent and Pluvicto OK with AR agent](https://longbridge.com/en/news/295360866.md)
- [Arvinas posts corporate presentation highlighting PROTAC degrader pipeline in oncology and neurology](https://longbridge.com/en/news/295231676.md)
- [FDA Approval Nearly Doubles Eligible Patient Pool For Novartis' Pluvicto](https://longbridge.com/en/news/294720619.md)
- [These Analysts Slash Their Forecasts On ANI Pharmaceuticals After Q2 Results](https://longbridge.com/en/news/295423642.md)
- [Yum China Q2 FY26 net income rises 14% to $244 million; revenue increases 13% to $3.14 billion](https://longbridge.com/en/news/295388910.md)